Get the Stockscreener App
1.17
0.85%
-0.01
Allogene Therapeutics Inc stock is traded at $1.17, with a volume of 3.00M.
It is down -0.85% in the last 24 hours and down -24.03% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.18
Open:
$1.18
24h Volume:
3.00M
Relative Volume:
0.91
Market Cap:
$255.91M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.5519
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
+10.38%
1M Performance:
-24.03%
6M Performance:
-52.82%
1Y Performance:
-52.44%
1-Day Range:
$1.10
$1.205
1-Week Range:
$1.03
$1.205
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.17 | 231.85M | 95,000 | -327.27M | -239.25M | -2.12 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Australia
Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com
Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia
Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times
Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq
Breakthrough: First-Ever Allogeneic CAR T Therapy Shows Efficacy Against Solid Tumors in Kidney Cancer Trial - Stock Titan
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus
ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2025 Earnings Call Transcript - Insider Monkey
Allogene Therapeutics (ALLO) Price Target Cut by Citi Amid Timel - GuruFocus
Allogene Therapeutics (ALLO) Price Target Cut by Citi Amid Timeline Delays | ALLO Stock News - GuruFocus
Allogene Therapeutics (ALLO) Price Target Lowered by Truist Securities | ALLO Stock News - GuruFocus
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Allogene Therapeutics (ALLO) Stock Drops Amid Trial Delays - GuruFocus
RBC Capital Reiterates Outperform Rating for Allogene Therapeuti - GuruFocus
Allogene Therapeutics (ALLO) Downgraded by Citizens JMP | ALLO S - GuruFocus
Piper Sandler Lowers Price Target for Allogene Therapeutics (ALL - GuruFocus
Allogene Therapeutics stock falls on trial delay, downgrade - Seeking Alpha
Allogene Therapeutics (ALLO): Price Target Lowered by Analyst | - GuruFocus
Piper Sandler Lowers Price Target for Allogene Therapeutics (ALLO) | ALLO Stock News - GuruFocus
Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating - marketscreener.com
Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer - GuruFocus
Allogene Therapeutics (ALLO) Price Target Lowered by Oppenheimer | ALLO Stock News - GuruFocus
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News
Allogene (ALLO) Pioneers Future of Cell Therapy with Innovative Strategies | ALLO Stock News - GuruFocus
Truist Lowers Price Target for Allogene Therapeutics (ALLO) Amid Trial Delays | ALLO Stock News - GuruFocus
Allogene Therapeutics (ALLO) Target Price Adjusted by Oppenheimer | ALLO Stock News - GuruFocus
Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating - marketscreener.com
Allogene Therapeutics (ALLO) Sees Price Target Reduction by Anal - GuruFocus
Allogene Therapeutics price target lowered to $9 from $10 at Oppenheimer - TipRanks
Allogene Therapeutics (ALLO) Price Target Reduced Amid Trial Del - GuruFocus
Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com
Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential - TipRanks
Allogene Therapeutics (ALLO) Downgraded by Citizens JMP | ALLO Stock News - GuruFocus
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):